Bio-Path completes first dose cohort in Phase 1 trial of BP1002 for lymphoma/CLL

BIO-PATH HOLDINGS, INC.

BP1002, a liposomal Bcl-2 antisense, advanced to next dose cohort (40 mg/m²) after completing 20 mg/m² cohort safely.
Trial targets refractory/relapsed lymphoma and CLL patients, including those who failed venetoclax-based therapy.
Phase 1 uses 3+3 design; six evaluable patients per cohort; enrollment open for second cohort.
BP1002 targets Bcl-2 mRNA, potentially overcoming BH3 domain mutations causing venetoclax resistance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.